XORTX Therapeutics shares surge 11.6% after-hours after extending deadline to acquire renal anti-fibrotic program from Vectus Biosystems.

XORTX Therapeutics surged 11.61% in after-hours trading following an overnight update on its acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems, including the novel compound VB4-P5. The company extended the acquisition deadline to March 31, 2026, to facilitate the transfer of intellectual property for VB4-P5, a preclinical asset with potential to address kidney fibrosis—a condition affecting 37 million U.S. patients and lacking approved therapies. The acquisition, supported by patents in over 30 jurisdictions, expands XORTX’s pipeline into a high-unmet-need market, aligning with the stock’s sharp post-market rise.